A5080587618- Platelet Disorders and Treatments
- Blood groups and transfusion
- Vascular Malformations and Hemangiomas
- Central Venous Catheters and Hemodialysis
- Hemophilia Treatment and Research
- Vascular Malformations Diagnosis and Treatment
- Gastrointestinal disorders and treatments
- IgG4-Related and Inflammatory Diseases
- Abdominal vascular conditions and treatments
- Autoimmune and Inflammatory Disorders Research
- Brain Metastases and Treatment
- Childhood Cancer Survivors' Quality of Life
- Acute Myeloid Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- Glioma Diagnosis and Treatment
- Virus-based gene therapy research
- Neutropenia and Cancer Infections
- Cancer Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Cytomegalovirus and herpesvirus research
- Polyomavirus and related diseases
- Histiocytic Disorders and Treatments
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Blood transfusion and management
Our Lady's Hospital
2014-2020
Children's Health Ireland at Crumlin
2016-2020
Birmingham Children's Hospital
2017
Irish Blood Transfusion Service
2017
In-Q-Tel
2016
Boston Children's Hospital
2015
Children's Hospital
2014
St. James's Hospital
2008
SUMMARY Background HLAMatchmaker has been used in the Irish Blood Transfusion Service ( IBTS ) to select platelets for HLA ‐alloimmunised, platelet refractory thrombocytopaenic patients since 2006. Although available 2002, only three studies have published supporting programme's effectiveness this indication. Objectives We sought examine increments ‐matched HMPs at various matchmaker scores and impact of transfusing older ABO ‐mismatched patient group. Methods/Materials A total 20...
An 8-week-old male infant presented with an 8 × 5 cm left posterior thoracic mass. The mass was first detectable at 4 weeks of age as a small, soft, skin-coloured lesion in thriving infant. Thereafter, it rapidly enlarged, becoming firm and purpuric. Severe thrombocytopenia present, the platelet count being 109/l, schistocytes were seen blood film. Prothrombin time, activated partial thromboplastin time thrombin all mildly prolonged fibrinogen 0·22 g/l (normal 1·54–4·55). D-dimers >10 000...
G-CSF post-allogeneic HSCT accelerates neutrophil engraftment, but evidence that it impacts on cost-related outcomes is lacking. We performed a retrospective child and adolescent single-center cohort study examining administration from Day +6 of allogeneic vs. ad hoc use where clinically indicated. Forty consecutive children adolescents undergoing were included. End-points as follows: time to engraftment; incidence acute chronic GvHD; number patients alive at +100; 180-day TRM;...